BUZZ-Anti-TIGIT drugmakers down as Roche's lung cancer drug fails trial

Reuters07-05

(Updates)

** U.S.-listed shares of Israel-based therapy developer Compugen fall ~3% to $1.62 premarket

** Switzerland-based Roche's drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday

** CGEN has colorectal, ovarian and lung cancer treatments in development that work by acting on the TIGIT receptor, which suppresses the proliferation and activation of cells of the immune system

** Other anti-TIGIT drugmakers Iteos Therapeutics down 8.6% and Arcus Biosciences down 3.5%

** Up to last close, CGEN down 15.6%, RCUS down 24.8% and ITOS up 35% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment